-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1243 Clinical and Serological Characteristics of Vaccine-Associated Immune Thrombocytopenia Following COVID-19 Vaccination

Program: Oral and Poster Abstracts
Session: 331. Thrombotic Microangiopathies/Thrombocytopenias: Clinical and Epidemiological: Poster I
Hematology Disease Topics & Pathways:
Research, Bleeding and Clotting, Autoimmune disorders, Adult, Epidemiology, Clinical Research, Platelet disorders, Diseases, Immune Disorders, Adverse Events, Study Population, Human
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Reid C. Gallant, MD, MSc1, Melanie St John2*, Yang Liu, MMath2*, Madison Cranstone2*, John G. Kelton, MD, FRCPC2, Ishac Nazy, PhD3 and Donald Arnold, MD2

1Department of Medicine, McMaster University, Mississauga, ON, Canada
2Michael G. DeGroote Centre for Transfusion Research, McMaster University, Hamilton, ON, Canada
3Department of Medicine, McMaster University, Hamilton, ON, Canada

Introduction: Vaccine-associated immune thrombocytopenia (VA-ITP) is a serious hematological complication that re-emerged during COVID-19 vaccination campaigns and continues to complicate vaccine safety. The mechanisms of VA-ITP are unknown, and the associated laboratory and patient outcomes have not been well characterized. In this study, we determined the association of VA-ITP with anti-platelet autoantibodies.

Methods: We conducted a retrospective cohort study of adult patients with VA-ITP following COVID-19 vaccination identified from the McMaster ITP Registry between December 2020 and January 2024. VA-ITP was defined as new-onset thrombocytopenia (platelet count <100 x109/L) within 3 months of exposure to vaccination. We excluded patients with vaccine-induced immune thrombotic thrombocytopenia (VITT) and positive anti-PF4 antibodies. Platelet counts, vaccine type, and treatments were collected. Platelet antibody testing was performed using a direct monoclonal antibody immobilization of platelet antigens (MAIPA) assay to detect antibodies against platelet glycoprotein (GP) IIbIIIa and GPIbIX. Anti-PF4 antibodies were also measured in the enzyme-immunoassay (EIA) and in the PF4-enhanced serotonin release assay (PF4-SRA). The data were summarized using descriptive statistics.

Results: We identified 6 VA-ITP patients after COVID-19 vaccination from the McMaster ITP Registry. Mean age was 52 years (range 28–70), 2 (33.3%) were female. Culprit vaccines were the ChAdOx1 nCoV-19 adenoviral vector (n=3, 50%; first vaccine only), and the BNT16B2b2 mRNA vaccine [n= 3, 50%; after first (n=1), third (n=1) or fourth vaccine (n=1)]. Median platelet count pre-vaccination was 248 x109/L (IQR 197 – 249 x109/L), and median presenting platelet count was 12 x109/L (IQR 9 – 82 x109/L) at 19.5 days (median; IQR 14 – 23 days) post vaccination. Median lowest platelet count was 7 x109/L (IQR 3 – 11 x109/L), occurring 65 days (median; IQR 57 – 384 days) post vaccination. No patients had thrombosis.

Three (50%) of 6 patients had detectable platelet antibodies up to 156 days post-vaccination (range 70 – 247 days). Two patients had anti-GPIbIX only and 1 patient had both anti-GPIbIX and anti-GPIIbIIIa. Two patients had received the adenoviral vector vaccine, and one patient received the mRNA vaccine.

Treatments for VA-ITP included corticosteroids (n=6), IVIg (n=5), thrombopoietin receptor agonists (n=3), rituximab (n=2), and splenectomy (n=1). Median number of treatments was 3 (IQR 3 – 4). One patient (16.7%) achieved a durable platelet count response, and 5 patients (83.3%) achieved an initial platelet count response and subsequently relapsed, requiring ongoing treatment at the end of follow up (median, 29.5 months; IQR 21.5 – 31).

Among the 3 patients with anti-GPIbIX or anti-GPIIbIIIa antibodies, median number of treatments was 4 (range 3 – 5), median lowest platelet count was 6 x109/L (range 3 – 8 x109/L), and all had relapsed requiring ongoing treatment at the end of follow up. Among the 3 antibody-negative patients, the median number of treatments was 3 (range 2 – 3), median lowest platelet count was 11 x109/L (range 1 – 71 x109/L), and 2 (66.7%) required ongoing treatment at the end of follow up. All 6 patients received a median of 2.5 booster vaccines (IQR 1 – 4) during follow up; 2 patients (33.3%) experienced a decrease in platelet counts ≥20%, but none developed severe ITP.

Conclusion: We found that 3 (50%) of 6 patients with VA-ITP after adenoviral vector and mRNA COVID-19 vaccines had detectable anti-platelet antibodies, including 2 patients with anti-GPIbIX and one patient with both anti-GPIbIX and anti-GPIIbIIIa. Antibody-positive VA-ITP tended to be more severe and require more treatment.

Disclosures: Arnold: Amgen: Consultancy; Argenx: Consultancy; Medison: Consultancy; Principia: Consultancy; Rigel: Consultancy; Sanofi: Consultancy; Sobi: Consultancy; Novartis: Research Funding; Paradigm: Research Funding.

*signifies non-member of ASH